CL2013000174A1 - Deposito farmaceutico que comprende 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1h-pirazol-3-il)amino]piridin-3-carbonitrilo y un polimero que se degrada para liberar el principio activo; su uso en la prevención o el tratamiento de osteoartritis. - Google Patents

Deposito farmaceutico que comprende 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1h-pirazol-3-il)amino]piridin-3-carbonitrilo y un polimero que se degrada para liberar el principio activo; su uso en la prevención o el tratamiento de osteoartritis.

Info

Publication number
CL2013000174A1
CL2013000174A1 CL2013000174A CL2013000174A CL2013000174A1 CL 2013000174 A1 CL2013000174 A1 CL 2013000174A1 CL 2013000174 A CL2013000174 A CL 2013000174A CL 2013000174 A CL2013000174 A CL 2013000174A CL 2013000174 A1 CL2013000174 A1 CL 2013000174A1
Authority
CL
Chile
Prior art keywords
fluoro
amino
carbonitrile
pyrazol
osteoarthritis
Prior art date
Application number
CL2013000174A
Other languages
English (en)
Inventor
Emily Fuller
Armelle Janin
Philip Macfaul
Rachel Pugh
Ian Nash
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44511084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000174(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2013000174A1 publication Critical patent/CL2013000174A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Depósito farmacéutico que comprende 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1h-pirazol-3-il)amino]piridin-3-carbonitrilo y un polímero que se degrada para liberar el principio activo; su uso en la prevención o el tratamiento de osteoartritis.
CL2013000174A 2010-07-19 2013-01-18 Deposito farmaceutico que comprende 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1h-pirazol-3-il)amino]piridin-3-carbonitrilo y un polimero que se degrada para liberar el principio activo; su uso en la prevención o el tratamiento de osteoartritis. CL2013000174A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36540710P 2010-07-19 2010-07-19

Publications (1)

Publication Number Publication Date
CL2013000174A1 true CL2013000174A1 (es) 2013-03-08

Family

ID=44511084

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000174A CL2013000174A1 (es) 2010-07-19 2013-01-18 Deposito farmaceutico que comprende 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1h-pirazol-3-il)amino]piridin-3-carbonitrilo y un polimero que se degrada para liberar el principio activo; su uso en la prevención o el tratamiento de osteoartritis.

Country Status (19)

Country Link
US (2) US20120022110A1 (es)
EP (1) EP2595608A2 (es)
JP (1) JP2013535443A (es)
KR (1) KR20130137592A (es)
CN (1) CN103108627A (es)
AR (1) AR082291A1 (es)
AU (1) AU2011281323A1 (es)
BR (1) BR112013001489A2 (es)
CA (1) CA2804725A1 (es)
CL (1) CL2013000174A1 (es)
CO (1) CO6670578A2 (es)
EC (1) ECSP13012447A (es)
MX (1) MX2013000774A (es)
RU (1) RU2013104639A (es)
SG (1) SG186929A1 (es)
TW (1) TW201208685A (es)
UY (1) UY33517A (es)
WO (1) WO2012010883A2 (es)
ZA (1) ZA201301246B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108871607B (zh) 2018-08-13 2020-01-03 太原理工大学 一种面向分布式光纤拉曼传感器的高精度温度解调方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
BR9815499A (pt) * 1997-07-02 2001-01-02 Euro Celtique Sa Anestesia prolongada nas juntas e nos espacos corporais.
CN100528224C (zh) * 2004-09-27 2009-08-19 中国人民解放军军事医学科学院毒物药物研究所 含干扰素α-1b的注射用缓释微球及其制备方法
CN1631362A (zh) * 2004-11-26 2005-06-29 中国科学院上海药物研究所 一种抗肿瘤控释组合物及其制备方法
US20060140988A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Visco-supplement composition and methods
CN1308034C (zh) * 2004-12-27 2007-04-04 中山大学 一种干扰素聚乳酸－羟乙酸共聚物plga微球的制备方法
MX2007009437A (es) * 2005-02-04 2007-08-16 Astrazeneca Ab Derivados de pirazolilaminopiridina utiles como inhibidores de cinasa.
US20070141160A1 (en) * 2005-12-15 2007-06-21 Brown Laura J Method of treatment for osteoarthritis by local intra-articular injection of microparticles
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
CN100457187C (zh) * 2006-11-10 2009-02-04 中国人民解放军第二军医大学 Vegf缓释注射微球支架及其制备方法和用途
US8153112B2 (en) * 2007-08-03 2012-04-10 Warsaw Orthopedic, Inc. Compositions and methods for treating cavity conditions
US20090281150A1 (en) * 2008-04-09 2009-11-12 Nicola Frances Bateman Compound 249

Also Published As

Publication number Publication date
AR082291A1 (es) 2012-11-28
CN103108627A (zh) 2013-05-15
CA2804725A1 (en) 2012-01-26
RU2013104639A (ru) 2014-08-27
ZA201301246B (en) 2014-05-28
US20120022110A1 (en) 2012-01-26
WO2012010883A3 (en) 2012-09-07
CO6670578A2 (es) 2013-05-15
JP2013535443A (ja) 2013-09-12
UY33517A (es) 2012-02-29
AU2011281323A1 (en) 2013-02-28
KR20130137592A (ko) 2013-12-17
SG186929A1 (en) 2013-02-28
BR112013001489A2 (pt) 2016-05-31
EP2595608A2 (en) 2013-05-29
WO2012010883A2 (en) 2012-01-26
US20140045895A1 (en) 2014-02-13
MX2013000774A (es) 2013-03-22
ECSP13012447A (es) 2013-03-28
TW201208685A (en) 2012-03-01

Similar Documents

Publication Publication Date Title
CL2013003577A1 (es) Uso de una composicion farmaceutica que comprende panobinostat y ruxolitinib en la prevencion y/o tratamiento de neoplasias mieloproliferativas.
IN2014DN06529A (es)
CL2012003745A1 (es) Compuestos derivados de aminopirazoloquinazolinas, como inhibidores frente a la actividad fosforilante del receptor igf-1 localizado en membranas celulares; preparacion farmaceutica que los contiene; y su uso en el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2008001123A1 (es) Compuestos derivados de acido lipoico; formulacion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
PH12015500115B1 (en) Glucagon analogues
CL2012003293A1 (es) Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson.
BR112012024835A2 (pt) adesivo de distribuição transdérmica
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
CL2013000018A1 (es) Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros.
CL2008002893A1 (es) Compuestos derivados de n-fenil-(piridin-3-il) acetamida sustituidas; composicion farmaceutica; procedimiento de preparacion; y su uso para prevenir o tratar el cancer.
EA201190295A1 (ru) Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
RS53466B (en) USE OF AMISULPRID FOR THE TREATMENT OF POSTOPERATIVE Nausea and Vomiting
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
UY32520A (es) Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
EA201390979A1 (ru) Композиции бензимидазолов с модифицированным высвобождением
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
CL2012001757A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas.
NI201100008A (es) Nuevas posibilidades de lucha contra la giardiasis.
MX359713B (es) Composiciones mejoradas para la cicatrizacion de heridas que comprenden microesferas.
CL2008000091A1 (es) Compuestos derivados de piridina, inhibidores del receptor p2y12; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento del trastorno de agregacion plaquetaria.
EA201390646A1 (ru) Фармацевтические композиции
IL222568A0 (en) Non-intravenous dosage form comprising solid formulation of liquid biologically active agent and uses thereof